Breast Cancer
Conference Coverage
Therapy ups breast cancer survivors’ cardiac risks
WASHINGTON – Anthracycline-based chemotherapy, anti-HER2 agents, and radiation all increase the risk for subsequent heart disease in breast cancer...
From the Journals
Clinical relevance of tamoxifen pharmacogenetics in question
Investigators found no significant association between endoxifen concentrations or CYP2D6 genotyping and relapse-free survival in patients with...
Conference Coverage
Single-cell genomics drive progress toward human breast cell atlas development
SAN ANTONIO – Improved understanding of the cellular landscape of both normal breast tissue and breast cancer could...
From the Journals
AML, myeloma risk higher for breast cancer survivors
Risk for both myeloid and lymphoid neoplasms was higher among breast cancer survivors than in the general population.
News
FDA approves third trastuzumab biosimilar
The drug is approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
From the Journals
High postpartum breast cancer metastasis risk may persist for a decade
Analysis of more than 700 patients showed that risk of metastasis was approximately twofold higher for a decade after childbirth, with risks about...
Feature
Progress in cancer research slowed by broken system
Unreported conflicts of interest are just one component of a broken system, according to a former chief medical officer for the ACS, the president...
Latest News
Soy didn’t up all-cause mortality in breast cancer survivors
The ongoing study tracks with previous work showing no risk from dietary soy.
Daily News Podcast
Daily News Special: SABCS
The latest clinical medicine news from the 2018 annual San Antonio Breast Cancer Symposium.
From the Journals
Neoadjuvant degarelix more effective than triptorelin for ovarian suppression
Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist approved for prostate cancer, was more effective than the GnRH agonist triptorelin...
From the Journals
Actionable mutations more likely in women with both breast and uterine cancer
At least one actionable mutation was seen in 14% of women with breast and uterine cancer, compared with 9.3% of women with breast cancer only, in...